期刊文献+

小剂量安体舒通对社区单纯收缩期高血压患者血压影响的临床研究

Effects of small dose of spironolactone on the patients with isolated systolic hypertension in community
下载PDF
导出
摘要 目的:研究小剂量安体舒通对单纯收缩期高血压(isolated systolic hypertension,ISH)患者血压的影响。方法:83例ISH患者随机分为治疗组和对照组,在继续目前降压治疗的基础上,治疗组患者每天服用安体舒通10 mg,对照组患者每天服用维生素C 0.3 g,比较治疗前和治疗13周后两组患者的血压和电解质、血肌酐水平。结果:与治疗前相比,治疗组患者的收缩压明显降低,而舒张压和血钾水平没有明显变化,对照组的收缩压、舒张压以及血钾和血肌酐水平没有明显变化。结论 :小剂量的安体舒通可以安全有效地降低ISH患者的收缩压。 Objective: To study the effect of small dose of spironolactone on the patients with isolated systolic hypertension (ISH) in community. Methods: Eighty-three cases of ISH patients were randomly divided into a treatment group and a control group. Based on the original antihypertensive treatment, patients in the treatment group took spironolactone at a dose of 10 mg daily while vitamin C 0.3 g daily in the control group. Blood pressure, electrolytes and serum creatinine levels in all patients were detected before treatment and 13 weeks after treatment. Results: Systolic blood pressure (SBP) was significantly reduced, and diastolic blood pressure (DBP) and serum potassium levels had no significant change in the treatment group 13 weeks after treatment while SBP, DBP, serum potassium levels and serum creatinine levels had no significant change in the control group. Conclusion: The SBP of patients with ISH can be safely and effectively reduced by taking a small dose of spironolactone.
出处 《上海医药》 CAS 2014年第21期34-36,共3页 Shanghai Medical & Pharmaceutical Journal
关键词 安体舒通 单纯收缩期高血压 血压 spironolactone isolated systolic hypertension blood pressure
  • 相关文献

参考文献15

  • 1中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):579-616. 被引量:4551
  • 2Vanhanen H, Thijs L, Birkenhager W, et al. Prevalence and persistency of orthostatic blood pressure fall in older patients with Isolated systolic hypertension[J]. J Hum Hyperten, 1996, 10(9): 607-612.
  • 3Vaclavik J, Sedlak R, Plachy M, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT) -- study protocol[J]. Biomed Pap Meal Fac Univ Palacky Olomouc Czech Repub, 2011, 155(2): 143-148.
  • 4Pepe S, Lakatta EG. Aging hearts and vessels : masters ofadaptation and survival[J]. Cardiovase Res, 2005, 66(2): 190- 193.
  • 5Wu Z, Yao C, Zhao D, et al. Sino-MONICA project: a collaborative study on trends and determinants in cardiovascular diseases in China. Part i: morbidity and mortality monitoring[J]. Circulation, 2001, 103(3): 462-468.
  • 6Safar ME. Pulse presure, arterial stifness and wave reflections (augumentation index) was a cadiovascular risk factors in hypertension[J]. Cadiovasc Dis, 2008, 2(1): 13-24.
  • 7Jamse MA, Robinson TG, Panerai RB, et al. Arterial baroreceptor cardiac reflex sensitivity in the eldedy[J]. Hypertension, 1996, 28(6): 953-960.
  • 8Hozawa A, Ohkubo T, Naqai K, et al. Progrosis of isolated systolic and isolated diastolic hypertension as asseaaed by self-management of blood presrue at home. The Ohsama study[J]. Arch Intern Med, 2000, 160(21): 3301-3306.
  • 9Beckett NS, Peers R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older[J]. N Eng J Med, 2008, 358(18): 1887-1898.
  • 10Messerli FH, Panjrath GS. The J-curve between blood presure and coronary artery disese or essential hypertension: exactly how enssential[J]. J Am coil Cadiol, 2009, 54(20): 1827-1834.

二级参考文献23

  • 1Moser M, Setaro JF. Resistant or difficult-to-control hypertension[J]. N Engl J Med,2006,355 : 385-392.
  • 2Jodi H, Marcel R, Swapnil H, et al. Spironolactone for difficult to control hypertension in chronic kidney dis- ease: an analysis of safety and efficacy[J].J Am Socie- ty Hypertension, 2010, 4: 295-301.
  • 3Va'clavik J, Sedlalk R, Plachy' M, et al. Addition of Spironolaetone in Patients with Resistant Arterial Hy- pertension (ASPIRANT) : A randomized,double-blind, placebo-controlled trial [J].Hypertension, 2011, 57: 1069-1075.
  • 4de Souza F, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension[J].Hypertension, 2010,55 : 147-152.
  • 5Saha C, Eckert GJ, Ambrosius WT, et al. Improve- ment in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension[J]. Hyper- tension,2005,46 : 481-487.
  • 6London GM. Role of arterial wall properties in the pathogenesis of systolic hypertension[J]. Am J Hyper- tens, 2005,18 : 19S-22S.
  • 7Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, et al. Management o5 resistant arterial hyperten- sion., role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system[J]. J Hyper-tens, 2010,28:2329-2335.
  • 8Franklin SS, Khan SA, Wong ND, et al. Is pulse pres- sure useful in predicting risk for coronary heart disease? The Framingham Heart Study[J]. Circulation, 1999, 100:354 -360.
  • 9Pitt B, Zannad F, Remme WJ, et al. The effect of spi- ronolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators[Jl. N Engl J Med, 1999,341: 709- 717.
  • 10Vizzardi E, D'Aloia A, Giubbini R, et al. Effect of spi- ronolactone on left ventricular ejection fraction and vol- umes in patients with class I or Ⅱ heart failure[J].Am J Cardiol,2010,106 : 1292-1296.

共引文献4636

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部